AGER Blocking Peptide (Center)

AGER Blocking Peptide (Center)

€363.00
In stock
SKU
AC-BP21684c
Catalog Number: AC-BP21684c
Size: 500 µg
Datasheet
Request Information
Background:
Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF- alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.

Other Names:
Advanced glycosylation end product-specific receptor, Receptor for advanced glycosylation end products, AGER, RAGE

Target/Specificity:
The synthetic peptide sequence is selected from aa 194-208 of HUMAN AGER

Gene Name: AGER

Gene ID: 177
Primary Accession: Q15109
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
More Information
Is Featured? No
Write Your Own Review
You're reviewing:AGER Blocking Peptide (Center)